Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes

DOI: 10.1016/j.virol.2014.10.032
Virology, 2015, 475, 37-45.

#	Paper	IF	Citations
24	Development of SHIVs with circulating, transmitted HIV-1 variants. *Journal of Medical Primatology*, **2015**, 44, 296-300	0.7	16
23	Animal models in HIV-1 protection and therapy. *Current Opinion in HIV and AIDS*, **2015**, 10, 170-6	4.2	38
22	Immune correlates of vaccine protection against HIV-1 acquisition. *Science Translational Medicine*, **2015**, 7, 310rv7	17.5	142
21	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. *Journal of Virology*, **2015**, 89, 8643-50	6.6	40
20	Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. *Journal of Immunology*, **2016**, 196, 3064-78	5.3	42
19	Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences. *Current Opinion in HIV and AIDS*, **2016**, 11, 546-554	4.2	26
18	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E3413-22	11.5	132
17	Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy. *Current Topics in Microbiology and Immunology*, **2018**, 417, 69-109	3.3	11
16	A single gp120 residue can affect HIV-1 tropism in macaques. *PLoS Pathogens*, **2017**, 13, e1006572	7.6	20
15	What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection. *Cold Spring Harbor Perspectives in Biology*, **2018**, 10,	10.2	21
14	High throughput generation and characterization of replication-competent clade C transmitter-founder simian human immunodeficiency viruses. *PLoS ONE*, **2018**, 13, e0196942	3.7	4
13	HIV-1 Latency. *Current Topics in Microbiology and Immunology*, **2018**,	3.3	1
12	Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. *Viruses*, **2018**, 10,	6.2	4
11	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. *Nature Communications*, **2018**, 9, 2363	17.4	24
10	Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen. *Journal of Virology*, **2019**, 93,	6.6	5
9	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. *PLoS Pathogens*, **2019**, 15, e1007632	7.6	9
8	Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. *Journal of Virology*, **2020**, 94,	6.6	2

7	Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge. *Frontiers in Immunology*, **2020**, 11, 626464	8.4	2
6	Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages. *Viruses*, **2021**, 13,	6.2	0
5	Optimized Mucosal MVA Prime/ Soluble gp120 Boost Vaccination Regimen Induces Similar Antibody Responses as an Intramuscular Regimen.		1
4	Adapting SHIVs In Vivo Selects for Envelope-Mediated Interferon-Resistance. *PLoS Pathogens*, **2016**, 12, e1005727	7.6	10
3	Oral clade C SHIV challenge models to study pediatric HIV-1 infection by breastmilk transmission.		1
2	Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus.		
1	Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus. **2022**, 13,		0